Filing Details
- Accession Number:
- 0001104659-15-049012
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-30 18:45:33
- Reporting Period:
- 2015-06-30
- Filing Date:
- 2015-06-30
- Accepted Time:
- 2015-06-30 18:45:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1454789 | Catabasis Pharmaceuticals Inc | CATB | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1291884 | Medimmune Ventures, Inc. | One Medimmune Way Gaithersburg MD 20878 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-06-30 | 1,079,115 | $0.00 | 1,079,115 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2015-06-30 | 330,098 | $0.00 | 1,409,213 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2015-06-30 | 223,439 | $12.00 | 1,632,652 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2015-06-30 | 13,866,666 | $0.00 | 1,079,115 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2015-06-30 | 4,241,780 | $0.00 | 330,098 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Footnotes
- The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- These shares are owned directly by MedImmune Ventures, Inc. Ron Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.